An inhibitor of PDE5
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

MBCQ

Item No. 21017

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-(1,3-benzodioxol-5-ylmethyl)-6-chloro-4-quinazolinamine
CAS Number
150450-53-6
Molecular Formula
C16H12ClN3O2
Formula Weight
313.7
Purity
≥98%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMSO: 5 mg/ml
λmax
294, 326, 339 nm
SMILES
ClC1=CC2=C(C=C1)N=CN=C2NCC3=CC(OCO4)=C4C=C3
InChi Code
InChI=1S/C16H12ClN3O2/c17-11-2-3-13-12(6-11)16(20-8-19-13)18-7-10-1-4-14-15(5-10)22-9-21-14/h1-6,8H,7,9H2,(H,18,19,20)
InChi Key
CNODHOSDWZLJGA-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $36

    Add

    5 mg

    $95

    Add

    10 mg

    $169

    Add
    Product Description

    MBCQ is an inhibitor of phosphodiesterase 5 (PDE5; IC50 = 19 nM).1 It is selective for PDE5 over PDE1, PDE2, PDE3, and PDE4 (IC50s = >100 µM for all). It induces relaxation of isolated porcine coronary arteries precontracted with prostaglandin F2α (PGF2α; EC50 = 190 nM).

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Takase, Y., Saeki, T., Watanabe, N., et al. Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity. J. Med. Chem. 37(13), 2106-2111 (1994).